< Back to Pediatric Cancer Research Studies Page
This phase I/II trial studies the side effects and best dose of liposomal cytarabine-daunorubicin CPX-351 (CPX-351) when given with fludarabine phosphate, cytarabine, and filgrastim and to see how well they work in treating younger patients with acute myeloid leukemia that has come back aft
To determine the activity of lenalidomide in the treatment of pediatric subjects with relapsed/refractory AML (with second or greater relapse or refractory to at least 2 prior induction attempts) measured by morphological complete response defined as either a CR or CRi within the fir
PURPOSE: The purpose of this study is to test the safety of a study drug
called CPX-351. This drug has been tested in adults but not yet in children and
adolescents. This study tests different doses of the drug to see which dose is
safer in children and adolescents.
Patients who have blood ca
To learn more about available leukemia clinical trials, contact us at firstname.lastname@example.org or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2017 Cincinnati Children's Hospital Medical Center. All rights reserved.